[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553718":3},{"organization":4,"outcomesModule":7,"designInfo":33,"detailedDescription":32,"studyPopulation":36,"armGroups":37,"interventions":32,"overallOfficials":44,"centralContacts":52,"locations":32,"responsibleParty":60,"collaborators":62,"id":65,"slug":32,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":32,"eligibilityCriteria":69,"healthyVolunteers":70,"sex":71,"minAge":72,"maxAge":32,"enrollmentInfo":73,"targetDuration":76,"studyType":77,"phases":32,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":88,"whyStopped":32,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":32},{"fullName":5,"class":6},"University of Zurich","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":32},[9],{"measure":10,"description":11,"timeFrame":12},"Change in pulmonary artery pressure in highlanders","Change in pulmonary artery pressure (RV\u002FRA measured by echocardiography) from 2017 to 2024 in highlanders living above 2500 m.","Year 2017 to 2024",[14,17,20,23,26,29],{"measure":15,"description":16,"timeFrame":12},"Change in pulmonary artery pressure between highlanders and lowlanders","Difference in the change in pulmonary artery pressure (RV\u002FRA measured by echocardiography) from 2017 to 2024 between highlanders and lowland controls.",{"measure":18,"description":19,"timeFrame":12},"Change in TRP\u002FCO in highlanders","Change in TRP\u002FCO slope from 2017 to 2024 in highlanders living above 2500 m.",{"measure":21,"description":22,"timeFrame":12},"Progression of oxygen desaturation index","Change in the oxygen desaturation index from 2017 to 2024 in highlanders.",{"measure":24,"description":25,"timeFrame":12},"Progression of quality of life","Change in the mental and physical component score of the SF-36 questionnaire from 2017 to 2024 in highlanders.",{"measure":27,"description":28,"timeFrame":12},"Progression of arterial blood gases","Change in the arterial blood gases from 2017 to 2024 in highlanders.",{"measure":30,"description":31,"timeFrame":12},"Progression of right heart strain","Change in the right heart strain from 2017 to 2024 in highlanders.",null,{"allocation":32,"interventionModel":32,"interventionModelDescription":32,"primaryPurpose":32,"observationalModel":34,"timePerspective":35,"maskingInfo":32},"COHORT","PROSPECTIVE","Highlanders living at Aksay plateau will be invited to participate.",[38,41],{"label":39,"type":32,"description":40,"interventionNames":32},"Highlanders living above 2500 m","Highlanders permanently living above 2500 m in the Aksay area in Kyrgyzstan",{"label":42,"type":32,"description":43,"interventionNames":32},"Low altitude control","Healthy lowlanders living below 1000 m.",[45,49],{"name":46,"affiliation":47,"role":48},"Talant M Sooronbaev, Prof. Dr.","National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov","PRINCIPAL_INVESTIGATOR",{"name":50,"affiliation":51,"role":48},"Silvia Ulrich, Prof. Dr.","University Hospital Zurich, Department of Pulmonology",[53,57],{"name":50,"role":54,"phone":55,"phoneExt":32,"email":56},"CONTACT","+41442552220","silvia.ulrich@usz.ch",{"name":58,"role":54,"phone":55,"phoneExt":32,"email":59},"Michael Furian, Prof. Dr.","michael.furian@usz.ch",{"type":61,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR",[63],{"name":47,"class":64},"OTHER_GOV","100553718",false,"NCT06489730","HAPH Registry: Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders.","Inclusion Criteria:\n\n* Permanently living \\>2500 m\n* Written informed consent\n\nExclusion Criteria:\n\n* Highlanders who cannot follow the study investigations,\n* Patients with moderate to severe concomitant lung disease (FEV1\\\u003C70% or forced vital capacity \\\u003C70%), severe parenchymal lung disease, heavy smoking \\>20 cigarettes\u002Fday or \\>20 pack-years.\n* Coexistent unstable systemic hypertension or coronary artery disease that required adjustment of medication within the last 2 months\n* Regular use of medication that affects control of breathing (benzodiazepines, opioids, acetazolamide)",true,"ALL","18 Years",{"count":74,"type":75},120,"ESTIMATED","7 Years","OBSERVATIONAL","The purpose of the current study is to evaluate the clinical and physiologic course of Kyrgyz highlanders with high altitude pulmonary hypertension (HAPH) by performing a longitudinal cohort study. To this end, the investigators will invite the same highlanders who participate din the study in 2017 to undergo follow-up examinations in 2024, in order to allow comparisons of current results with baseline data from 2017.",[80,81],"High Altitude Pulmonary Hypertension","Sleep Apnea",[83,84,85,86,87],"high altitude illness","pulmonary hypertension","sleep apnea","disease progression","hypoxia","NOT_YET_RECRUITING","2024-06-28",{"date":91,"type":92},"2024-07-08","ACTUAL",{"date":94,"type":75},"2024-07-01",{"date":96,"type":75},"2024-12-31",{"name":5,"class":6}]